Polish recommendations for the management of ITP in adults developed by the Hemostasis Group of the Polish Society of Hematologists and Transfusiologists — update 2024

Streszczenie

Primary immune thrombocytopenia (ITP) is a rare disease diagnosed by exclusion of other causes of thrombocytopenia. Nearly 14 years [1] have passed since the publication of the first edition of the Guidelines, during which time significant progress has been made in the treatment of ITP. The main aim of the present work is to update the principles of management in ITP. These recommendations are limited to the treatment of adult patients with ITP. The management of children with this disease will be published separately. Secondary immune thrombocytopenia has also been omitted from these guidelines. Although a platelet response can be achieved in secondary ITP by using the same drugs as in the primary form, the cornerstone of treatment for secondary forms is the removal of the immunization cause. The recommendations were based on research results and guidelines prepared by experts from other countries [2, 3]. The final shape of the document was prepared during consensus conferences involving members of the Haemostasis Group of the Polish Society of Hematology and Transfusion Medicine, which took place in 2023 and 2024. The primary recipients of the recommendations are physicians providing care for patients with ITP, as well as primary care physicians.